FAQ on NanoViricides' Participation in D. Boral Capital Inaugural Global Conference
Summary
What is NanoViricides, Inc.?
NanoViricides, Inc. is a clinical-stage company developing broad-spectrum antivirals using host-mimetic nanomedicine technology, focusing on treatments for RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections.
When and where is the D. Boral Capital Inaugural Global Conference taking place?
The conference is scheduled for May 14, 2025, at The Plaza Hotel in New York City.
Who from NanoViricides will be presenting at the conference?
Anil R. Diwan, President and Executive Chairman of NanoViricides, is scheduled to host one-on-one meetings with investors from 9 a.m. to 3 p.m. ET.
What is NanoViricides’ lead drug candidate?
NanoViricides’ lead drug candidate is NV-387, a broad-spectrum antiviral drug aimed at treating RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections.
Where can I find more information about NanoViricides?
For more information about NanoViricides, visit their website at www.NanoViricides.com or check the latest news and updates in the company’s newsroom at https://ibn.fm/NNVC.
What is the significance of NanoViricides’ participation in the conference?
NanoViricides’ participation highlights its innovative nanomedicine technology and its potential to revolutionize antiviral therapy, offering investors and the public insight into its progress and future plans.
What other drug candidates does NanoViricides have?
Besides NV-387, NanoViricides has NV-HHV-1 for the treatment of Shingles and NV-CoV-2-R, a drug candidate for COVID-19 that encapsulates remdesivir within its polymeric micelles.
How does NanoViricides’ technology work?
NanoViricides’ technology involves creating special purpose nanomaterials for antiviral therapy, based on intellectual property and proprietary know-how from TheraCour Pharma, Inc., focusing on mimicking host cells to combat viruses.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 117177